The global market for Cancer Supportive Care Products is poised for significant growth in 2020, with an approximate year-on-year increase of 4%. This growth is propelled by the increasing demand for effective solutions to manage chemotherapy-induced anemia, where erythropoietin-stimulating agents are at the forefront, commanding a significant share of the revenue.
Hospital Pharmacies Maintain Stronghold in Sales Through 2030
Cancer patients and healthcare providers continue to rely on hospital pharmacies as a reliable source of cancer-supportive care products. This trend is expected to persist and remain prominent throughout the next decade, ensuring that patients have ready access to the support they require.
Accelerated Use of Cancer Supportive Care Products in Leukemia Treatment
The utilization of cancer-supportive care products in the treatment of leukemia is expected to gain momentum in the coming years. This development reflects the evolving landscape of cancer care and the role of supportive products in improving patient outcomes.
Get a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-2550
North America Leads the Way in the Global Cancer Supportive Care Products Industry
Over the next decade, North America is set to spearhead the global market for cancer-supportive care products. This region’s leadership is attributed to its advanced healthcare infrastructure, increasing patient awareness, and a robust commitment to cancer care.
In an environment where every healthcare choice matters, it’s essential not to pay for what you don’t need. Stay informed, make informed decisions, and ensure you have the most suitable supportive care products for your unique requirements.
Efforts to manage drug expenditure have channeled the focus towards cancer-supportive care products, especially in developed regions, where value-based health-technology assessments (HTAs) are prevalent.
The cancer supportive care products industry is characterized by a rapidly growing and globalized standard of medical care. Case in point, in non-small-cell lung cancer, the number of approved therapies was estimated to rise from 14 in 2009 to 22 by 2019.
This, coupled with limited data during accelerated approvals, implies that manufacturers are working in close collaboration with payers to create a value proposition for cancer-supportive care products.
Key Takeaways of Cancer Supportive Care Products Industry Study
- Incidences of cancer have surged by around 26% among geriatric demographics compared to 10% among the remaining population
- Adoption of cancer supportive care products to remain prominent in treating lung cancer
- Pharma companies to invest 30% of their spending in cancer R&D to launch novel drugs and therapies in the marketplace
- Market in Asia Pacific (APAC) to experience meteoric growth through 2030
Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/REP-GB-2550
COVID-19 Impact on Cancer Supportive Care Products Industry
The COVID-19 pandemic has touched every facet of human life including, healthcare delivery for chronic disorders.
As such, these patients are highly susceptible to getting infected by COVID-19 due to their compromised immunity, putting cancer specialists and patients in a dilemma.
Several healthcare facilities are deferring “elective” screenings, surgeries, and other methods that are considered not urgent or not immediately fatal.
Such important decisions are taken on a case-to-case basis to make sure patients diagnosed with cancer are protected from contracting the coronavirus as well as to ensure that healthcare facilities are equipped with the resources necessary to treat cancer patients who are affected by the virus.
The COVID-19 crisis has disturbed the treatment pathways and in-progress care, thus, resulting in a temporary drop in demand for cancer-supportive care products.
“To address the untapped sections of society, several regulatory bodies are showing immediacy in granting approvals to certain cancer-supportive care products. Case in point, the US Food and Drug Administration (FDA) has approved Pfizer’s Nyvepria to help prevent infections in patients undergoing myelosuppressive chemotherapy,” says the analyst at FMI.
Cancer Supportive Care Products Industry – Competitive Intelligence
The cancer supportive care products market is highly competitive, with the presence of several small- and medium-sized players. Manufacturers are leveraging innovation into their best practices to have proper capabilities in place and stay ahead in the fast-growing and competitive arena.
- Baxter International Inc. develops products under the business categories of renal Care, Medication Delivery, and Pharmaceuticals. The company develops REGLAN Injection, which is a metoclopramide injection.
- Amgen Inc. makes and provides innovative human therapeutics – Neulasta, which is a PEGylated form of human granulocyte CSF.
Understanding the study’s underlying assumptions. Unlock Insights from the Masters
https://www.futuremarketinsights.com/ask-question/REP-GB-2550
Want more insights?
Future Market Insights, in its new study, provides compelling insights about the cancer supportive care products market that encloses industry analysis for 2015 – 2019 and opportunity assessment for 2020 – 2030.
The report offers an unbiased assessment of the cancer supportive care products industry through four different categories – by drug class, by indication, by distribution channel, and by region.
The global cancer-supportive care products market research study delivers insights into pricing by different life cycle analyses, product life cycle, major market trends, and technologies that are being utilized in the development of cancer-supportive care products and product adoption in various end-use sectors
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube